Analysis by Product {Immunoglobulins (Intravenous, and Subcutaneous), Coagulation Factors, and Albumin}; by Application (Immunology, Hematology, Critical Care, Rheumatology, and Neurology); and End-User (Hospitals, Clinical Research Lab, and Academic Institutes) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Buy Now
The global plasma fractionation market is estimated to garner a revenue of ~USD 37 billion by the end of 2033 by growing at a CAGR of ~ 7% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 26 billion in the year 2022. The growth of the market is primarily attributed to the rising prevalence of bleeding disorders that occur when there is an issue that opposes the body’s blood clotting procedure. Based on the U. S. Centers for Disease Control estimates, there are nearly 3 million people nationwide, who have been suffering from bleeding disorders.
Get more information on this report:Download Sample PDF
Immunoglobulins are derived from the fractionation of plasma and are very effective in treating various neurologic, immunologic, and hematologic diseases. Hence, the increasing prevalence of immunological diseases among the population is anticipated to increase the need for immunoglobulins & alpha-1-antitrypsin in numerous areas of medicine. In addition to that, the increased focus on characterizing and diagnosing immunodeficiency is also expected to generate a high demand for plasma fractionation in the next few years owing to the high number of diagnosed patients. Further, another major factor expected to contribute to the growth of the market is the surge in plasma collection centers across the globe. For instance, a pioneer in the creation of plasma-derived medicines, Grifols has opened its 300th plasma donation site in the United States, the second in New England and the first in the state of Massachusetts.
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~ 7% |
|
Base Year Market Size (2022) |
~ USD 26 Billion |
|
Forecast Year Market Size (2033) |
~ USD 37 Billion |
|
Regional Scope |
|
Growth Drivers
Proliferation in the Number of Chronic Diseases –There have been growing cases of chronic disease, which has increased the demand for its treatments. Among various treatments, plasma therapy is the most extensively used treatment. Hence, the plasma fractionation market is expected to grow further over the forecast period. For instance, the most common and expensive medical illnesses in the US are chronic diseases. About 133 million Americans, or roughly 45% of the population, have at least one chronic illness, and the number is rising.
Growing Geriatric Population – Old people have a weakened immune system and are prone to both chronic and acute diseases. Thus, for effective diagnostic and treatment procedures plasma fractionation has become imperative which is projected to create a positive outlook by the end of the forecast period. According to the World Health Organization figures, by 2030, one in every six persons on the planet would be 60 or older.
Increased Investment by Major Players in Effective Treatment – For instance, CSL Behring & Takeda Pharmaceutical Company Ltd. collaborated with Biotest, BPL, LFB, and Octapharma to develop an effective plasma-derived drug for the treatment of COVID-19.
Increasing Autoimmune Diseases - According to current estimates, the number of autoimmune disease cases worldwide is increasing between 3% to approximately 10% yearly.
Unhealthy Lifestyle Involving Consumption of Alcohol, Tobacco, and Fast Food – The recent shift of the population towards an unhealthy lifestyle has made the human body weak and with a low resistance to fight diseases and illnesses. As a result, for the diagnosing and treatment of these disorders, the demand for products from plasma fractionation is forecasted to increase in the upcoming years. According to the Centers for Disease Control and Prevention, 25.1% of adults aged 18 and over in the world are reported to have at least one day of heavy drinking (five or more drinks for males and four or more drinks for women) during the previous year.
Challenges
The global plasma fractionation market is segmented and analyzed for demand and supply by application into immunology, hematology, critical care, rheumatology, and neurology. Out of these, the neurology segment is anticipated to garner the largest revenue by the end of 2033, backed by increasing cases of neurological disorders such as Alzheimer, and Parkinson’s. According to the Pan America Health Organization, in 2019, neurological diseases were responsible for 533,172 deaths in the region, with men accounting for 213,129 (40%) and women accounting for 320,043 (60%). Also, the application of immunoglobulin is supposed to increase in the forecast period for treating cases of chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis, and inflammatory myopathies, thus expanding the segment share in the forecast period. Also, the rise in old age patients suffering from neurological disease across the globe along with increased research activities for using IVIG for neurology indications is another factor that is considered to bring growth opportunities.
The global plasma fractionation market is also segmented and analyzed for demand and supply by end-user in hospitals, clinical research labs, and academic institutes. Out of these, the hospitals segment is attributed generate the highest revenue during the forecast period. The major factor that is attributed to fuel the segment’s growth is the increasing adoption of plasma fractionation products in treating various disorders which includes autoimmune disease, neurological diseases, bleeding, and other disorders, along with the increased patient pool opting for plasma-derived therapies worldwide. Further, the growing number of hospitals in every region of the world and the presence of plasma donation centers in hospitals are also estimated to fuel the segment’s growth. Other growth factors for the segment development include rising investments in the hospital infrastructure, and the expansion of the healthcare sector.
Our in-depth analysis of the global plasma fractionation market includes the following segments:
|
By Application |
|
|
By Product
|
|
|
By End-User |
|
The North America plasma fractionation market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The high number of hemophilic patients along with the rising prevalence of other chronic diseases in the region is considered to be the major factor for the market growth in the region. In addition, the escalation in health disorders, including severe fever with thrombocytopenia syndrome (SFTS), hemophilia, and immune deficiencies, is also considered a growth factor for the market.
On the flip side, the European plasma fractionation market is also estimated to garner a significant share by the end of the assessment period. The major factors for the market growth in the region are attributed to the rising cases of immunodeficiency and bleeding disorders among Europeans. For instance, the total number of patient identified with a specific PI defect increased by 45.2% in Western Europe, and by 25.7% in Eastern Europe from 2013 to 2021.Furthermore, the increased count of blood plasma collection facilities across the region, and favorable regulations from the government are further propelling the growth of the plasma fractionation market over the assessment period in the region.
CSL Limited
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: The major factors driving the growth of the market are increase In number of chronic diseases, growing geriatric population, increased investment by major players, and others.
Ans: The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2033.
Ans: High cost related to plasma therapy, increasing use of recombinant alternatives, and restricted medical reimbursement policies are some of the major factors expected to hinder the growth of the market.
Ans: The market in Europe is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
Ans: The major players in the market are CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, Kedrion S.p.A and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, application, end-user, and by region.
Ans: The neurology segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
